A type of peptide used in diabetes and weight-loss drugs might help calm inflammation in joint cells.
Evidence from Studies
Supporting (2)
Community contributions welcome
Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
The study tested a diabetes drug called liraglutide, which activates GLP-1 receptors, and found it reduced joint cell inflammation, including a key chemical called PGE2. This supports the idea that similar drugs can calm joint inflammation.
The study tested a diabetes drug called liraglutide in cartilage cells and found it reduced inflammation, which supports the idea that this type of drug can calm inflammation in joint cells.
Contradicting (1)
Community contributions welcome
The study looked at whether a diabetes drug reduces inflammation in people with alcohol use disorder, but it didn’t look at joint cells or the specific substances mentioned in the claim, and it found no reduction in inflammation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.